Related Experiment Video
Updated: Oct 12, 2025
06:10
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
3.4K
Hyperkalemia in Patients With Left Ventricular Assist Devices
Teruhiko Imamura1,2, Nikhil Narang2,3, Pamela Combs4
1Second Department of Internal Medicine, University of Toyama Toyama Japan.
Circulation Reports
|November 22, 2021
Summary
Hyperkalemia, or high potassium levels, is linked to increased mortality in patients with left ventricular assist devices (LVADs). Careful management of serum potassium is crucial for these patients.
Area of Science:
- Cardiology
- Medical Devices
- Electrolytes
Background:
- Both hypo- and hyperkalemia are known risk factors for adverse events in heart failure patients.
- The impact of potassium imbalances on patients with left ventricular assist devices (LVADs) is not well understood.
Purpose of the Study:
- To investigate the association between serum potassium levels and mortality in patients with LVADs.
- To determine if hypokalemia or hyperkalemia poses a greater risk in this population.
Main Methods:
- A cohort of 170 patients undergoing LVAD implantation between 2014 and 2018 was analyzed.
- Patients were stratified into three groups based on serum potassium levels one month post-implantation: hypokalemia (<3.5 mEq/L), normokalemia, and hyperkalemia (>5.0 mEq/L).
- One-year mortality rates were compared across the groups using adjusted hazard ratios.
Main Results:
- Hyperkalemia was associated with a significantly increased risk of 1-year mortality (adjusted HR: 4.14, 95% CI: 1.47-11.65) compared to normokalemia.
- Hypokalemia did not show a significant association with increased mortality (adjusted HR: 0.91, 95% CI: 0.21-3.92).
- In the hyperkalemia group, renin-angiotensin-aldosterone system inhibitor use decreased, and potassium levels normalized post-initial assessment.
Conclusions:
- Hyperkalemia is an independent risk factor for increased mortality in patients supported by LVADs.
- Further research is needed to establish optimal management strategies for serum potassium levels in LVAD patients.
More Related Videos
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
53
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
53
01:29Cardiomyopathy V: Interprofessional Care
64
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
64
01:30Cardiomyopathy II: Dilated Cardiomyopathy
63
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
63
01:26Heart Failure Drugs: Inotropic Agents
819
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
819
01:22Heart Failure Drugs: Diuretics
523
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
523
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
93
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
93